OrthoPediatrics Corp. Announces First Quarter 2026 Financial Results and Increases Guidance

OrthoPediatrics Corp. reported its first quarter 2026 financial results, with total revenue reaching $59.4 million, a 13% increase year-over-year. Domestic revenue grew 11% to $45.3 million, while international revenue surged 22% to $14.1 million. Trauma & Deformity revenue increased by 14% to $43.0 million, and Scoliosis revenue rose by 13% to $15.4 million. The company achieved an adjusted EBITDA of $2.2 million, a significant improvement from a loss of $0.4 million in the prior year's first quarter. Free cash flow usage decreased by 40% compared to the same period in 2025. OrthoPediatrics has increased its full-year 2026 revenue guidance to a range of $263.0 million to $267.0 million, representing 11% to 13% growth over 2025. The company expects to generate approximately $25.0 million of adjusted EBITDA and achieve breakeven free cash flow for the full year 2026.